Baxalta — Q4 2015 Earnings Presentation
46 slides from Baxalta's earnings presentation, Feb 16, 2016
Slide 1: Fourth Quarter 2015 Financial Results And Business Performance Update
Exhibit 99.2 Baxalta Incorporated Fourth Quarter 2015 Financial Results And Business Performance Update th February 16 , 2016
Slide 2: Forward-Looking Statements And GAAP Reconciliation
Forward-Looking Statements And GAAP Reconciliation “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: This presentation includes forward-looking statements concerning expectations, prospects, estimates and other matters that are dependent upon future events or develo
Slide 3: Table Of Contents
Table Of Contents
Slide 4: Strong Execution Validates Baxalta's Commitment To Enhancing Shareholder Value
Strong Execution Validates Baxalta’s Commitment To Enhancing Shareholder Value Sustaining growth and value across the portfolio • Generating positive sales momentum across broad and diversified portfolio • Demonstrating compelling commercial, regulatory, operational & financial execution Achieving ~
Slide 5: Driving Sustainable Growth And Value
Driving Sustainable Growth And Value Leadership Capabilities Value $6 billion global 100+ countries of ~20 new product biopharmaceutical operation launches expected by 2020 leader 2015 Sales By Product Category* 2015 Sales By Geography* $ In Millions $ In Millions $1,750 $2,915 $787 $6.2B $766 $6.2B
Slide 6: Generating Positive Momentum Across Portfolio
Generating Positive Momentum Across Portfolio Hematology* Immunology* Oncology Q4 2015 FY 2015 Q4 2015 FY 2015 Q4 2015 FY 2015 Strong ADVATE and FEIBA Completed ONCASPAR Enhanced supply position FY performance acquisition ADYNOVATE approval and Strong market acceptance Received EU approval of launch
Slide 7: Exceeding Sales Expectations Across All Product Categories
Exceeding Sales Expectations Across All Product Categories % Growth At Constant Currency FY 2015 FY 2015 FY 2015 Original * Guidance ** Actual Results ** (Q1 Conference Call) (Q3 Conference Call) Hemophilia 0% - 2% ~3% +4% Inhibitor Therapies 8%+ 10% - 11% +16% Hematology 2% - 3% ~5% +7% Immunoglobu
Slide 8: Our Pipeline Is Delivering Results
Our Pipeline Is Delivering Results Key Regulatory Approvals ONIVYDE 20% IGSC New Products In EU U.S./EU Regulatory Review New Product Revenue New Product ~$300 Million ~$750 Million 2015 Actual Results 2016 Guidance Launches By 2020 Baxalta Performance Update | Q4 2015 | Page 8
Slide 9: Achieving Key Milestones
Achieving Key Milestones ADYNOVATE Launched in U.S.; met primary endpoint in Phase III pediatric study VONVENDI Received U.S. regulatory approval OBIZUR Received EU approval; recently launched in EU BAX 826 Initiated Phase I trial targeting once-weekly dosing regimen for hemophilia A Gene Therapy FI
Slide 10: ~20 New Launches Expected By 2020
~20 New Launches Expected By 2020 Hematology Immunology Oncology ONIVYDE Imalumab (BAX 069) Pancreatic Cancer Malignant Ascites Post-Gemcitabine [U.S.] [Japan] ONIVYDE Imalumab (BAX 069) ONIVYDE ONCASPAR rd st Pancreatic Cancer 3 line Metastatic 1 line Gastric ALL Post-Gemcitabine Colorectal Cancer
Slide 11: Advancing External Innovation Through Successful Partnerships And Acquisitions
Advancing External Innovation Through Successful Partnerships And Acquisitions Partnerships Acquisitions Baxalta Performance Update | Q4 2015 | Page 11
Slide 12: Baxalta: A Compelling & Unique Investment Opportunity
Baxalta: A Compelling & Unique Investment Opportunity • Established $6 billion global biopharmaceutical leader focused on orphan diseases • Well positioned in attractive and growing markets with differentiated therapies Leadership • Strong global channels and patient relationships and potential to b
Slide 13: Innovation Highlights
Innovation Highlights Baxalta Q4 2015 Performance Update Baxalta Performance Update | Q3 2015 | Page 2
Slide 14: Building A Robust And Diverse Pipeline: Key Programs
Building A Robust And Diverse Pipeline: Key Programs* Program Pre-Clinical Phase I Phase II Phase III Reg. Review Approved EHL rFVIII PEG (BAX 855) EU Japan U.S. VONVENDI (BAX 111) EU U.S. OBIZUR: Acquired Hemophilia A EU rADAMTS13 (BAX 930) FIX Gene Therapy (BAX 335) EHL rFVIII PSA (BAX 826) FVIII
Slide 15: Broadest Portfolio Of Hemophilia Treatments
Broadest Portfolio Of Hemophilia Treatments Portfolio Advancement Towards Strength Of Hemophilia Portfolio Elevated & Sustained Factor Levels Delivers Sustainable Growth Base Extended Gene • EHL category represents ~35% of U.S. FVIII Half-Life Therapy patient share by 2020; ~45% by 2025 ADVATE ADYNO
Slide 16: Transforming Hemophilia Care With Gene Therapy
Transforming Hemophilia Care With Gene Therapy • Elevated trough direct-factor replacement with multi-year re-dosing potential • Development hurdles include wider patient eligibility, immune response, and re-dosing options • Baxalta leadership based on AAV8 progress and IP strength BAX 335 (FIX) BAX
Slide 17: FVIII Replacement Therapies Set High Bar For Hemophilia Treatments
FVIII Replacement Therapies Set High Bar For Hemophilia Treatments Non-Factor Approaches (i.e. ACE 910) Additional Benefits Of FVIII May Not Face Important Safety And Efficacy Be Replicated By Mimetics Limitations: • Lower affinity for FIXa and FX compared to 1 FVIII Wound Inflammation 2 Healing • O
Slide 18: Introducing Novel SuppreMol Treatments With Significant Potential
Introducing Novel SuppreMol Treatments With Significant Potential IgG Immune Fc RIIBAgonist IgE Competitive Complex Scavenger (IgG) Antagonist Receptor fragment protein Monoclonal antibody binds to Inhibits IgE mediated Mechanism binds to circulating immune inhibitory receptor to actively down aller
Slide 19: Exciting Oncology Growth Prospects
Exciting Oncology Growth Prospects • Integral component of many ALL • Statistically significant survival benefit treatment guidelines - 5-FU/LV of 6.1 months versus 4.2 months • 90% cure rate for children; 50% in young Value adults; 30% in adults - 5-FU/LV of 3.1 months versus 1.5 months Proposition
Slide 20: 2016 Pipeline Catalysts
2016 Pipeline Catalysts Clinical Regulatory Product Advancements Filings Approvals Calaspargase Pegol (Phase III Data) Alpha-1 ONIVYDE BAX 2200 ONIVYDE GvHD Pancreatic 1 st Line Etanercept Pancreatic 2 nd Line (Initiate Phase III) (Initiate Phase III) (EU) (EU) HYQVIA BAX 923 MyPKFiT ONCASPAR CIDP (
Slide 21: Financial Summary
Financial Summary Baxalta Q4 2015 Performance Update Baxalta Performance Update | Q3 2015 | Page 2
Slide 22: 2H 2015 Adjusted Financial Results
2H 2015 Adjusted Financial Results* Q3 2015 Q4 2015 2H 2015 Actual Results Actual Results Actual Results Sales ($ in Millions) $1,595 $1,763 $3,358 Growth** +13% +10% +12% Gross Margin 61.9% 63.8% 62.9% Operating Margin 31.2% 29.0% 30.1% EBITDA Margin 34.4% 32.1% 33.2% Tax Rate 22.1% 20.9% 21.5% Dil
Slide 23: Exceeding Guidance Across Key Financial Metrics
Exceeding Guidance Across Key Financial Metrics* 2H 2015 2H 2015 2H 2015 Guidance Guidance Actual Results (Investor Conference) (Q3 Conference Call) Sales Growth** 2% - 3% 8% - 9% 12% Gross Margin 58% - 59% ~62% 63% Operating Margin ~29% ~31% 30% EBITDA Margin ~33% ~35% 33% Tax Rate 23% - 24% ~23% 2
Slide 24: Driving Strong Financial Results: Q4 And 2H 2015
Driving Strong Financial Results: Q4 And 2H 2015 Adjusted Sales Growth* Adjusted EPS** % Sales Growth At Constant Currency $ Per Diluted Share $1.13 12% 10% $0.57 Q4 2015 2H 2015 Q4 2015 2H 2015 Guidance Guidance Guidance Guidance *Growth rates are at constant currency and compare to 2014 pro forma
Slide 25: Enhancing Strong Gross Margin Profile
Enhancing Strong Gross Margin Profile* 2H 2015 Gross Margin Gross Margin Drivers % Of Sales • Favorable product mix driven by: 65% - Strong sales of higher-margin therapies 63% - ONCASPAR leukemia portfolio ~62% acquisition - rFVIII share retention 60% • Modest price improvements 58% - 59% • Foreign
Slide 26: Investing To Accelerate Future Growth
Investing To Accelerate Future Growth SG&A Expense R&D Expense • Selectively expanding our specialty • Successfully meeting key milestones, sales force advancing clinical trials • Investing in marketing initiatives to prepare and launch new products: • Building out medical affairs and R&D infrastruc
Slide 27: Q1 2016 Financial Guidance
Q1 2016 Financial Guidance Guidance Reflects: Q1 2016 Guidance* • Building strong sales momentum across all three businesses Hematology 4% - 5% • Absorbing expected foreign currency Immunology 5% - 7% headwinds (i.e., lower hedge gains) in gross margin with positive mix benefits Oncology ~$50Mw • In
Slide 28: Business Review
Business Review Baxalta Q4 2015 Performance Update Baxalta Performance Update | Q3 2015 | Page 2
Slide 29: Hematology
Hematology Hematology Positioned For Growth • Strengthening our hematology leadership with broad portfolio of treatment options Strong global Strengthening presence and growth leadership and • Building personalized care through sustainability patient-centric innovation • Elevating access to treatmen
Slide 30: Hematology: Q4 And FY 2015 Results
Hematology: Q4 And FY 2015 Results* Q4 2015 FY 2015 $ In Millions U.S. Int. Total U.S. Int. Total Hemophilia $375 $425 $800 $1,339 $1,501 $2,840 Growth +9% +1% +4% +5% +4% +4% Inhibitor Therapies $85 $145 $230 $295 $492 $787 Growth +25% +8% +14% +35% +9% +16% Hematology $460 $570 $1,030 $1,634 $1,99
Slide 31: Hematology: Quarterly Sales Growth
Hematology: Quarterly Sales Growth Hemophilia Inhibitor Therapies % Sales Growth At Constant Currency % Sales Growth At Constant Currency 20% 40% 15% 30% 10% 20% 33% 5% 10% 22% 9% 9% 17% 18% 8% 7% 7% 14% 12% 4% 4% 9% 2% 0% 0% 2% Q1 14 Q2 14 Q3 14 Q4 14 Q1 15 Q2 15 Q3 15 Q4 15 Q1 14 Q2 14 Q3 14 Q4 14
Slide 32: Unique And Attractive Global FVIII Market
Unique And Attractive Global FVIII Market Distinct Market Characteristics 2014 Global FVIII Market • High brand loyalty and very low patient turnover despite eight competitors U.S. OUS Emerging • Safety and efficacy are top ~ $6.5B Markets considerations OUS Established • Trusted safety profile requ
Slide 33: ADYNOVATE: Blockbuster Potential
ADYNOVATE: Blockbuster Potential Positioned To Grow And Lead EHL • ADYNOVATE launched in U.S. during Q4 2015 - Single-digit price premium to ADVATE on an annual cost of therapy basis Key Attributes - Manufacturing capacity in place to support launch Based on ADVATE: global rFVIII leader • Strong IP
Slide 34: Immunology
Immunology Immunology Positioned For Growth • Building leadership in global markets characterized by robust demand • Capitalizing on a broad, differentiated Driving global Capitalizing on awareness and transformational IG portfolio demand differentiation • Improving supply with flexible, cost- effec
Slide 35: Immunology: Q4 And FY 2015 Results
Immunology: Q4 And FY 2015 Results* Q4 2015 FY 2015 $ In Millions U.S. Int. Total U.S. Int. Total Immunoglobulin Therapies $370 $103 $473 $1,350 $400 $1,750 Growth +1% +8% +3% +6% +17% +9% BioTherapeutics $69 $138 $207 $258 $508 $766 Growth +11% +28% +22% +6% +21% +16% Immunology $439 $241 $680 $1,6
Slide 36: Immunology: Quarterly Sales Growth
Immunology: Quarterly Sales Growth Immunoglobulin Therapies Pro Forma BioTherapeutics* % Sales Growth At Constant Currency % Sales Growth At Constant Currency 15% 35% 10% 25% 13% 13% 12% 15% 5% 24% 9% 21% 22% 19% 15% 14% 5% 3% 3% 4% 2% 0% -2% -5% -11% -5% -15% Q1 14 Q2 14 Q3 14 Q4 14 Q1 15 Q2 15 Q3
Slide 37: Capitalizing On Transformational Differentiation With HYQVIA
Capitalizing On Transformational Differentiation With HYQVIA HYQVIA Source Of Patients Global PID Indication: ~8% CAGR* Internal Estimates % By Route Of Administration In 2020 GGL Cannibalization ~25% IGIV Naïve ~55% ~25% $3.0B IGSC Competitive IV/SC ~45% ~50% Capturing SubQ Leadership Position With
Slide 38: Flexible And Cost-Effective Capacity Supports Future Demand Growth
Flexible And Cost-Effective Capacity Supports Future Demand Growth Cost-Effective Expansion Baxalta Fractionation Capacity** Liters In Millions • Disciplined investment in capacity to support 8% annual growth in demand 20 8%+ CAGR • Internal network combined with Sanquin CMO provides cost-effective
Slide 39: Oncology
Oncology Oncology Positioned For Growth • Capitalizing on an attractive and growing market • Focusing on orphan diseases and targeted Extracting value with FDA approval reflects populations with significant unmet need geographic and significance of unmet indication expansions medical need • Collabor
Slide 40: GAAP To Pro Forma Non-GAAP Reconciliations
GAAP To Pro Forma Non-GAAP Reconciliations
Slide 41: Notice To Investors
Notice To Investors Non-GAAP Financial Measures: The financial information included in these schedules includes financial measures that are not calculated in accordance with generally accepted accounting principles (GAAP). Reconciliations of the GAAP to non-GAAP financial measures can be found on pa
Slide 42: Pro Forma Sales Reconciliation: Q4 2015
Pro Forma Sales Reconciliation: Q4 2015 Q4 2015 Q4 2014 % Growth @ Actual Rates % Growth @ Constant Rates U.S. International Total U.S. International Total U.S. International Total U.S. International Total Hemophilia $375 $425 $800 $343 $491 $834 9% (13%) (4%) 9% 1% 4% Inhibitor Therapies 85 145 230
Slide 43: Pro Forma Sales Reconciliation: Q3 2015
Pro Forma Sales Reconciliation: Q3 2015 Q3 2015 Q3 2014 % Growth @ Actual Rates % Growth @ Constant Rates U.S. International Total U.S. International Total U.S. International Total U.S. International Total Hemophilia $337 $390 $727 $318 $437 $755 6% (11%) (4%) 6% 7% 7% Inhibitor Therapies 78 130 208
Slide 44: GAAP To Non-GAAP Reconciliation: Gross Margin
GAAP To Non-GAAP Reconciliation: Gross Margin $ in millions Q3 2015 Q4 2015 2H 2015 Gross Margin $962 $1,082 $2,044 Gross Margin Percentage 60.3% 61.4% 60.9% Adjustments for special items 25 42 67 Adjusted Gross Margin $987 $1,124 $2,111 Adjusted Gross Margin Percentage 61.9% 63.8% 62.9% Baxalta Per
Slide 45: GAAP To Non-GAAP Reconciliation: Operating Income And EBITDA
GAAP To Non-GAAP Reconciliation: Operating Income And EBITDA GAAP-to-Non-GAAP Reconciliation Operating Income and EBITDA $ in millions Q3 2015 Q4 2015 2H 2015 Pre-tax Income $354 $123 $477 Pre-tax Income Margin 22.2% 7.0% 14.2% Adjustments for special items 140 366 506 Adjusted Pre-tax Income 494 48
Slide 46: GAAP To Non-GAAP Reconciliation: Diluted EPS
GAAP To Non-GAAP Reconciliation: Diluted EPS Q3 2015 Q4 2015 2H 2015 Diluted EPS $0.45 $0.14 $0.59 Adjustments for special items 0.11 0.43 0.54 Adjusted Diluted EPS $0.56 $0.57 $1.13 Baxalta has also presented guidance for Q1 2016 using the non-GAAP measure of Adjusted Diluted EPS. Baxalta projects